Wolfgang Miesbach/LinkedIn
May 13, 2026, 15:10
Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Rethinking Bleeding Risk in Anticoagulation.
At the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo delivered a fantastic talk on bleeding risk in patients receiving antithrombotic therapy – from AF and VTE to prosthetic valves, LV thrombus and acute coronary syndromes:
- Antithrombotic therapy is used across many indications, so managing bleeding risk is a daily challenge in routine practice.
- Major bleeding (incl. ICH) remains a major limitation of VKAs and DOACs, and ‘fear‑driven’ underdosing in real life is still common.
- High‑risk patients (age, renal impairment, prior bleeding) live within a narrow therapeutic window, making individualized decisions essential.
- Targeting FXI could help decouple thrombosis from hemostasis, with early data suggesting relevant bleeding reduction while preserving efficacy.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST
-
Jun 26, 2026, 07:10Saleh Shamse Basha: Why APTT Alone Can Be Misleading During UFH Monitoring
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk
-
Jun 26, 2026, 05:55Shinya Goto: How Newton’s Laws Shape Platelet Function
-
Jun 26, 2026, 05:50Andrew Emad: Five Years of Partnership, Innovation, and Impact at Africa Health ExCon 2026
-
Jun 26, 2026, 05:48Regan Bucciol: The Emerging Role of Erythrocytes in Thrombosis
-
Jun 26, 2026, 05:26Maxime Dely: Strengthening Skills in Plasma and Red Cell Exchange
-
Jun 26, 2026, 05:26Andreas Calatzis: Hidden Differences in Anti-Xa Testing